摘要
目的探讨恩替卡韦联合强肝胶囊治疗慢性乙型肝炎合并非酒精性脂肪肝患者的临床疗效。方法选取116例慢性乙型肝炎合并非酒精性脂肪肝患者,随机分为治疗组和对照组各58例。治疗组患者给予恩替卡韦联合强肝胶囊治疗,对照组患者单纯给予恩替卡韦治疗,2组均治疗24周。观察比较2组患者治疗前后肝功能指标、血脂指标、HBV DNA、体质量指数(BMI)、胰岛素抵抗指数(IRI)及肝脏B超检测结果变化情况。结果治疗24周后,治疗组BMI、IRI、TG、TC水平均较对照组明显降低(P均<0.05);2组治疗后ALT、AST、GGT水平均较治疗前明显降低(P均<0.05),且治疗组GGT水平明显低于对照组(P<0.05)。2组HBV DNA转阴率比较差异无统计学意义(P>0.05)。治疗组脂肪肝恢复正常率显著高于对照组(P<0.05)。结论恩替卡韦联合强肝胶囊治疗慢性乙型肝炎合并非酒精性脂肪肝具有协同、增效作用,可改善肝功能及降低血脂水平,逆转肝脏脂肪堆积,但对病毒学应答无明显影响。
Objective It is to investigate the clinical efficacy of entecavir combined with Qianggan capsule in the treatment of patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease. Methods 116 patients with chronic hepatitis B and nonalcoholic fatty liver disease were randomly divided into treatment group and control group,58 cases in each group. The patients in the treatment group were treated with entecavir plus Qianggan capsule,and patients in the control group were treated with entecavir alone. Both groups were treated for 24 weeks. The changes of indexes of liver function and blood lipid,HBV DNA,BMI,IRI and liver B-ultrasound were observed and compared between the two groups. Results After 24 weeks of treatment,the levels of BMI,IRI,TG,TC and GGT were significantly lower in the treatment group than those in the control group( P < 0. 05). The levels of ALT,AST,GGT were significantly decreased in the two groups after treatment( P < 0. 05),and the levels of GGT in the treatment group was higher than that in the control group( P < 0. 05). There was no significant difference in negative conversion ratio of HBV DNA between the two groups.The degree of hepatic steatosis was improved in the treatment group,and the normal rate of recovery was significantly higher than that in the control group( P < 0. 05). Conclusion For patients with chronic hepatitis B and nonalcoholic fatty liver disease,entecavir combined with Qianggan Capsule has synergistic and synergistic effects,which could improve liver function and reduce the levels of blood liquid,and reverse fat accumulation in the liver,but it has no effect on the virological response.
作者
汤莉伟
唐东旭
黄钟鸣
吴建秋
沈文娟
陈晓兰
单文艳
哈明昊
TANG Liwei;TANG Dongxu;HUANG Zhongming;WU Jianqiu;SHEN Wenjuan;CHEN Xiaolan;SHAN Wenyan;HA Minghao(The Seventh People’s Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China)
出处
《现代中西医结合杂志》
CAS
2019年第24期2648-2651,共4页
Modern Journal of Integrated Traditional Chinese and Western Medicine
基金
浦东新区卫生系统学科带头人培养计划资助项目(PWRd2011-06)
上海市卫生局科研课题基金资助项目(20124368)
上海市高级中西医结合人才培养计划项目(ZY3-RCPY-4-2010)
关键词
慢性乙型肝炎
恩替卡韦
强肝胶囊
非酒精性脂肪肝
chronic hepatitis B
entecavir
Qiangan capsule
nonalcoholic fatty liver disease
